

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

 Docket No.
 5934-01-EMA

In Re Application Of: Steven Alan Dunham, et al.

09/719867

Serial No.

Filing Date

Examiner

Group Art Unit

 Title: **METHODS OF IDENTIFYING AND CHARACTERIZING MUTATIONS WITHIN BACTERIAL DNA
 GYRASE AND FABI**

Address to:

 Assistant Commissioner for Patents
 Washington, D.C. 20231
37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
 2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

 Docket No.
 5934-01-EMA

09/719867

In Re Application Of: Steven Alan Dunham, et al.

Serial No.

Filing Date

Examiner

Group Art Unit


 Title: **METHODS OF IDENTIFYING AND CHARACTERIZING MUTATIONS WITHIN BACTERIAL DNA
 GYRASE AND FABI**
Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 23-0455 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*
 I certify that this document and authorization to charge
 deposit account is being facsimile transmitted to the United
 States Patent and Trademark Office (Fax. No.

) on _____
 (Date)
*Signature**Typed or Printed Name of Person Signing Certificate***Certificate of Mailing by First Class Mail**
 I certify that this document and fee is being deposited
 on _____ with the U.S. Postal Service as
 first class mail under 37 C.F.R. 1.8 and is addressed to the
 Assistant Commissioner for Patents, Washington, D.C.
 20231.
*Signature of Person Mailing Correspondence**Typed or Printed Name of Person Mailing Correspondence*
 *This certificate may only be used if paying by
 deposit account.



Signature

Dated: December 18, 2000

 Charles W. Ashbrook
 Registration No. 27,610

 Warner-Lambert Company
 2800 Plymouth Road
 Ann Arbor, MI 48105
 Tel. (734) 622-5215
 Fax (734) 622-1553

CC:

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 5934-01-EMA	SERIAL NO. 097719867
	APPLICANT STEVE ALAN DUNHAM, ET AL.	
	FILING DATE	GROUP

#7
248
10.5.01

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 6 8 6 5 9 0	11/11/97	Jacobs, Jr. et al.	536	23.1	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 8 2 6 7 7 4	28.08.96	Europe				x
	0 0 8 1 0 7 8	15.06.83	Europe				x
	0 6 8 8 8 7 3	27.12.96	Europe				x

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

	PCT International Search Report, PCT/US99/22118
	Deguchi et al., "Quinolone-Resistant <i>Neisseria gonorrhoeae</i> : Correlation of Alterations in the GyrA Subunit of DNA Gyrase and the ParC Subunit of Topoisomerase IV with Antimicrobial Susceptibility Profiles", <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 40, No. 4, 1996, pp 1020-1023 ✓
	Tanaka et al., "Development of Fluoroquinolone Resistance and Mutations Involving GyrA and ParC Proteins Among <i>Neisseria Gonorrhoeae</i> Isolates in Japan", <i>The Journal of Urology</i> , Vol. 159, 1998, pp 2215-2219 3
	Jones and Howard, "A Rapid Method for Recombination and Site-Specific Mutagenesis by Placing Homologous Ends on DNA Using Polymerase Chain Reaction", <i>Biotechniques</i> , US, Natick, MA, Vol. 10, No. 1, 1991, pp 62-66 4
	Kok et al., "Combining Localized PCR Mutagenesis and Natural Transformation in Direct Genetic Analysis of a Transcriptional Regulator Gene, <i>pobR</i> ", <i>Journal of Bacteriology</i> , Vol. 179, No. 13, 1997, pp 4270-4276 5
	Belland et al., " <i>Neisseria gonorrhoeae</i> acquires mutations in analogous regions of <i>gyrA</i> and <i>parC</i> in fluoroquinolone-resistant isolates", <i>Molecular Microbiology</i> , Vol. 14, No. 2, 1994, pp 371-380 6
	McMurry et al., "Triclosan targets lipid synthesis", <i>Nature</i> , Vol. 394, 1998, pp 531-532 8
	Deguchi et al., "DNA Gyrase Mutations in Quinolone-Resistant Clinical Isolates of <i>Neisseria gonorrhoeae</i> ", <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 39, No. 2, 1995, pp 561-563 8
	Weigel et al., " <i>gyrA</i> Mutations Associated with Fluoroquinolone Resistance in Eight Species of <i>Enterobacteriaceae</i> ", <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 42, No. 10, 1998, pp 2661-2667 9
	Heath et al., "Broad Spectrum Antimicrobial Biocides Target the FabI Component of Fatty Acid Synthesis", <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 46, 1998, pp 30316-30320 10
	Macek et al., "Inhibition of <i>E. coli</i> Enoyl-Acyl-Carrier-Protein Reductase", <i>FASEB Journal</i> , Vol. 13, No. 7Sup, 1999, pp A1350, abstract

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.